E- CASE REPORT

Response to Omalizumab in Solar Urticaria: Report of 3 Cases

P. Rodríguez-Jiménez, * P. Chicharro, A. Pérez-Plaza, D. de Argila

Servicio de Dermatología, Hospital Universitario de La Princesa, Madrid, Spain

KEYWORDS
Inducible chronic urticaria;
Omalizumab;
Solar urticaria

PALABRAS CLAVE
Urticaria crónica inducible;
Omalizumab;
Urticaria solar

Abstract  We report 3 cases of solar urticaria in which there was no response or limited response to first-line treatments with high-dose H1 antihistamines or phototherapy. The patients were then treated with omalizumab. Symptoms improved in 2 patients, whose tolerance to sunlight increased considerably; quality of life clearly improved for 1 of these patients. The third experienced no improvement and developed a mild local reaction to the injected medication. We conclude that omalizumab may offer a potentially safe, useful alternative for patients with solar urticaria who do not respond to conventional therapy.

© 2017 Elsevier España, S.L.U. and AEDV. All rights reserved.

Introduction

Solar urticaria (SU) is an uncommon chronic inducible urticaria characterized by the development of wheals after exposure to sun radiation, visible light, or UV radiation. Because the condition is rare, there are no epidemiological data on incidence or prevalence rates, although varying figures of between 2.3% and 17.8% have been reported within the group of photodermatoses. Lesions typically appear within minutes of exposure and the most common action...
spectra are visible light and UV-A. Action spectrum and minimal urticaria dose (MUD) are important for diagnosis, treatment, and prognosis, and can be used to rule out other photodermatoses.2

Second-generation H1 antihistamines are the first-line treatment for inducible chronic SU, just as they are for other forms of inducible chronic urticaria. However, most patients require either high doses or combinations of different antihistamines.3 An alternative first-line approach is tolerance induction through phototherapy.2 The use of omalizumab has also been described in several case reports and small case series of patients in recent years, with varying results. The principle underlying this treatment is based on a hypothetic role for immunoglobulin (Ig) E in the pathogenesis of inducible chronic urticaria.3

Case Descriptions

The clinical data for 3 patients with severe SU refractory to H1 antihistamines treated in our department over a period of 5 years are summarized in Table 1.

<table>
<thead>
<tr>
<th>Sex</th>
<th>Age, y</th>
<th>Com</th>
<th>TsO, y</th>
<th>PT</th>
<th>MUD</th>
<th>IgE</th>
<th>Dose During Treatment</th>
<th>Clinical Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>55</td>
<td>ARC</td>
<td>5</td>
<td>H1 A PT</td>
<td>Wheal after 30 min with VL</td>
<td>502 IU/mL</td>
<td>300 mg/mo 12 mo</td>
<td>Complete with negative provocation test results</td>
</tr>
<tr>
<td>F</td>
<td>65</td>
<td>PLE</td>
<td>10</td>
<td>H1 A</td>
<td>Wheal after 30 min with FL UV-B, 10 mj/cm²; UV-A, &lt;0.6 mj/cm²; SS, &lt;10 mj/cm²</td>
<td>17.2 IU/mL</td>
<td>300 mg/mo 6 mo</td>
<td>Partial</td>
</tr>
<tr>
<td>F</td>
<td>50</td>
<td>Unr</td>
<td>25</td>
<td>H1 A</td>
<td></td>
<td>1382 IU/mL</td>
<td>150 mg/2 wk 1.5 mo</td>
<td>No clinical or objective response</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>300 mg/mo 4 mo</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: ARC, allergic rhinoconjunctivitis; Com, comorbid conditions; FL, fluorescent light; H1 A, H1 antihistamines; IgE, immunoglobulin E; MUD, minimal urticaria dose; PLE, polymorphic light eruption; PT, previous treatment; TsO, time since onset; Unr, unremarkable; VL, visible light.

In our review of the literature, we identified 16 patients with SU treated with omalizumab (8 case reports and 3 case series).1-14 Fourteen of the patients were adults and 2 were children.5,6 The treatment doses varied between 150 mg/mo2 and 800 mg/mo.7 Varying measures of clinical response were used, and not all authors reported on this aspect of treatment. Most authors used subjective criteria based on patient-reported manifestations or other health-related quality of life measures. Others used phototesting6,9 or the Urticaria Activity Score 7, which is a validated tool for evaluating chronic urticaria.10 Of the 16 patients, 12 (75%) responded either partially or completely to treatment and 5 of these (31.2%) additionally showed negative provocation results. Follow-up time varied from 1 month, in a patient who showed complete response after a single dose,6 to 1 year, in a patient who received 12 monthly doses.6

On analyzing the cases reviewed, we observed a certain tendency towards an association between high total baseline IgE levels, albeit variable, and greater response to treatment. Seven of the 8 patients in this subgroup responded to treatment, although it should be noted that some of the responders had normal IgE levels, while some of the non-responders (like patient #3 in our series) had elevated levels.

No severe adverse effects were mentioned in the cases reviewed, and it is noteworthy that the treatment proved safe in the 2 pediatric cases described.5,6

Finally, Aubin et al.15 recently reported on results from a phase II clinical trial investigating the use of omalizumab (300 mg/mo for 2 months) in 10 patients with SU studied by phototesting and photoprovocation (action spectra: UV-A, UV-B, and polychromatic solar spectrum). The primary endpoint was the proportion of patients who did not develop SU lesions after photoprovocation with a UV radiation dose 10 times higher than the baseline MUD after 12 weeks of treatment. Approximately 40% of the patients showed an
initial clinical improvement, but the efficacy results based on the primary endpoint showed no significant differences.

In conclusion, despite the limited data available from case reports and small case series on the characteristics and results of SU treatment with omalizumab, the clinical response rate of 75% based on reports in the literature to date is promising. The 3 patients described in our series are a selection of patients with severe SU treated at our department and omalizumab proved effective in 2 of them. Response was slower than that typically described for spontaneous chronic urticaria, with improvement observed after 3 doses (patient #1) or 5 doses (patient #2). Both patients are satisfied with the results and wish to continue treatment. Omalizumab may therefore be a potentially safe and useful treatment for patients with severe SU that is refractory to conventional treatment.

Ethical Disclosures

Protection of humans and animals. The authors declare that no tests were carried out in humans or animals for the purpose of this study.

Confidentiality of data. The authors declare that they have followed their hospital’s protocol on the publication of data concerning patients.

Right to privacy and informed consent. The authors declare that no private patient data appear in this article.

Conflicts of Interest

Dr de Argila has worked as a clinical advisor for Novartis and also participated in clinical trials sponsored by this company. The other authors declare no conflicts of interest.

References